Table 1 Characteristics of normal controls, patients with and without 12-week mirabegron treatment.

From: Urinary beta 3-adrenoceptor as a diagnostic biomarker for overactive bladder in women

 

Normal (n = 35)

Non-treated OAB (n = 27)

Treated OAB (n = 23)

p valuea

Age (y)b

50.4 ± 11.2

52.5 ± 11.3

57.7 ± 12.5

0.068

BMI (kg/m2)b

22.7 ± 2.7

23.8 ± 3.5

23.0 ± 2.4

0.341

Married

24 (68.6%)

20 (74.1%)

15 (65.2%)

0.787

Parityc

1.7 ± 0.9

2.0 ± 1.5

2.2 ± 1.4

0.379

NSD

19 (54.3%)

19 (70.4%)

15 (65.2%)

0.409

Menopause

19 (54.3%)

18 (66.7%)

15 (65.2%)

0.549

Prior HT

2 (5.7%)

5 (18.5%)

3 (13.0%)

0.300

Smoking

2 (5.7%)

1 (3.7%)

2 (8.7%)

0.854

Medical diseases

7 (20.0%)

2 (7.4%)

5 (21.7%)

0.301

Prior Gyn surgeries

22 (62.9%)

17 (63.0%)

15 (65.2%)

0.981

  1. Data are presented as mean ± standard deviation and n (%).
  2. OAB, Overactive bladder; BMI, Body mass index; NSD, Normal vaginal delivery; HT, Hormonal therapy; Gyn, Gynecological.
  3. Medical diseases include hypertension, diabetes and heart diseases.
  4. Prior Gyn surgeries include uterine myomectomy, adnexal mass resection, fallopian tube ligation and cesarean section.
  5. aChi-squared test and the Fisher's exact test.
  6. bOne-way analysis of variance (ANOVA).
  7. cKruskal–Wallis test.
  8. *p < 0.05.
Back to article page